Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's ... The study was backed by ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

Alzheimer's Drug May Slow Down Cognitive Decline in ... to automaticaly quanitfy motor systems in early-stage Parkinson's ... New Visual Technique Could Advance Early Detection of ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

However, the new law would not be applicable to people ... What medication is available and what are the side effects?

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...